摘要
背景:线粒体损伤在阿尔茨海默病(AD)的病理生理学中起着重要作用。然而,在人类进行的研究几乎没有考虑与疾病进展的区域差异。 目的:研究编码线粒体复合物亚基的线粒体复合物亚基和线粒体复合物活性的选择性核基因在内嗅皮层(EC)和额皮质区8(FC)两个区域的表达。 方法:采用qRT-PCR技术从148例病例中分离出冷冻样本,利用商业试剂盒和自制的检测方法测定线粒体复合物I,II,IV和V的活性。 结果:复合体Ⅰ,Ⅱ,Ⅳ和Ⅴ的亚基NDUFA2,NDUFB3,UQCR11,COX7C,ATPD,ATP5L和ATP50的表达下降, II。然而,与EC中的中年个体相比,分离的线粒体的复合物I,II和V的活性在I-II阶段早期发生。相反,在同一系列的FC中没有发现相同基因的表达改变和线粒体复合物活性的改变。 结论:AD可能出现不同的能量代谢受损机制,其中以EC为代表的是线粒体初级和早期改变的结果;另一个可能是功能性输入功能下降的结果,并且在86岁或更小的AD患者中由FC代谢减弱来表示。
关键词: 阿尔茨海默病,线粒体,线粒体磷酸化,代谢减退,基因表达,额叶皮质,内嗅皮层。
Current Alzheimer Research
Title:Reduced Mitochondrial Activity is Early and Steady in the Entorhinal Cortex but it is Mainly Unmodified in the Frontal Cortex in Alzheimer's Disease
Volume: 14 Issue: 12
关键词: 阿尔茨海默病,线粒体,线粒体磷酸化,代谢减退,基因表达,额叶皮质,内嗅皮层。
摘要: Background: It is well established that mitochondrial damage plays a role in the pathophysiology of Alzheimer's disease (AD). However, studies carried out in humans barely contemplate regional differences with disease progression.
Objective: To study the expression of selected nuclear genes encoding subunits of the mitochondrial complexes and the activity of mitochondrial complexes in AD, in two regions: the entorhinal cortex (EC) and frontal cortex area 8 (FC).
Methods: Frozen samples from 148 cases processed for gene expression by qRT-PCR and determination of individual activities of mitochondrial complexes I, II, IV and V using commercial kits and home-made assays.
Results: Decreased expression of NDUFA2, NDUFB3, UQCR11, COX7C, ATPD, ATP5L and ATP50, covering subunits of complex I, II, IV and V, occurs in total homogenates of the EC in AD stages V-VI when compared with stages I-II. However reduced activity of complexes I, II and V of isolated mitochondria occurs as early as stages I-II when compared with middle-aged individuals in the EC. In contrast, no alterations in the expression of the same genes and no alterations in the activity of mitochondrial complexes are found in the FC in the same series.
Conclusion: Different mechanisms of impaired energy metabolism may occur in AD, one of them, represented by the EC, is the result of primary and early alteration of mitochondria; the other one is probably the result, at least in part, of decreased functional input and is represented by hypometabolism in the FC in AD patients aged 86 or younger.
Export Options
About this article
Cite this article as:
Reduced Mitochondrial Activity is Early and Steady in the Entorhinal Cortex but it is Mainly Unmodified in the Frontal Cortex in Alzheimer's Disease, Current Alzheimer Research 2017; 14 (12) . https://dx.doi.org/10.2174/1567205014666170505095921
DOI https://dx.doi.org/10.2174/1567205014666170505095921 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Hybrid Anticonvulsants Derived from Pyrrolidine-2,5-dione Scaffold with Broad Spectrum of Activity in the Preclinical Studies
Current Topics in Medicinal Chemistry A Critical Analysis of New Molecular Targets and Strategies for Drug Developments in Alzheimers Disease
Current Drug Targets Nutraceuticals and their Derived Nano-Formulations for the Prevention and Treatment of Alzheimer's Disease
Current Molecular Pharmacology Patent Selections :
Recent Patents on CNS Drug Discovery (Discontinued) Inflammatory Mechanisms and Oxidative Stress as Key Factors Responsible for Progression of Neurodegeneration: Role of Brain Innate Immune System
CNS & Neurological Disorders - Drug Targets Suppression of Glial HO-1 Activitiy as a Potential Neurotherapeutic Intervention in AD
Current Alzheimer Research CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation Use of STAT1 Inhibitors in the Treatment of Brain I/R Injury and Neurodegenerative Diseases
Central Nervous System Agents in Medicinal Chemistry Cannabinoids and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Preface [Hot topic: Current Pharmacotherapeutic Approaches to the Treatment of Cognitive Impairment in Alzheimers Disease and Related Disorders (Executive Editor : Bernd Ibach)]
Current Pharmaceutical Design The Roles of Phosphodiesterase 2 in the Central Nervous and Peripheral Systems
Current Pharmaceutical Design Protection Mechanisms Against Aβ42 Aggregation
Current Alzheimer Research Editorial (Thematic Issue: Alzheimer’s Disease - Mechanisms, Drug Targets and Alternative Treatments)
Current Topics in Medicinal Chemistry Neurobiology of Bipolar Disorder: Abnormalities on Cognitive and Cortical Functioning and Biomarker Levels
CNS & Neurological Disorders - Drug Targets Kinetics of In Vitro Inhibition of Acetylcholinesterase by Nineteen New Carbamates
Current Enzyme Inhibition In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer’s Disease Treatment
CNS & Neurological Disorders - Drug Targets Parkinson's Disease: A Role for the Immune System
Current Molecular Pharmacology Detection of the Active Components of Calf Thymus Nuclear Proteins (TNP), Histones that are Binding with High Affinity to HIV-1 Envelope Proteins and CD4 Molecules
Current HIV Research Clinical and Prognostic Implications of Cognitive Dysfunction and Depression in COPD
Current Respiratory Medicine Reviews Role of Nanomedicines in Delivery of Anti-Acetylcholinesterase Compounds to the Brain in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets